SCHEMBL710282

SCHEMBL710282

O=CCCCOCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
TEAD3 Q99594 2/20 0.44
HRH4 Q9H3N8 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
NAAA Q02083 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
EPHX2 P34913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6263416 1.00 TSHR (0.52) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL20305579 0.96 TSHR (0.48) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL713499 0.94 TSHR (0.50) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL9875114 0.93 L3MBTL1 (0.50) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL18585071 0.93 L3MBTL1 (0.50) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL5561948 0.93 L3MBTL1 (0.50) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL711369 0.93 L3MBTL1 (0.50) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL6211503 0.93 L3MBTL1 (0.50) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL1009942 0.93 L3MBTL1 (0.50) TSHRL3MBTL1TDP1TEAD3HRH4
SCHEMBL7784378 0.93 L3MBTL1 (0.50) TSHRL3MBTL1TDP1TEAD3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145368-B2 Organocatalytic synthesis of chiral pyrazolidines and their analogues COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-09-29 US claimed
US-20140357872-A1 NEW ORGANOCATALYTIC SYNTHESIS OF CHIRAL PYRAZOLIDINES AND THEIR ANALOGUES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-12-04 US claimed
WO-2013088456-A1 A NEW ORGANOCATALYTIC SYNTHESIS OF CHIRAL PYRAZOLIDINES AND THEIR ANALOGUES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-06-20 WO claimed
EP-1001943-B1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM AVENTIS PHARMA SA (FR) 2003-12-17 EP claimed
US-6380197-B1 FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES AVENTIS PHARMA S. A. (FR) 2002-04-30 US claimed
EP-1001943-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM Aventis Pharma S.A. (FR) 2000-05-24 EP claimed
WO-1999003843-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1999-01-28 WO claimed
JP-58152829-A None JP disclosed
EP-4142732-B1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-22 EP disclosed
EP-4720058-A2 BIFUNCTIONAL DEGRADERS AND USES THEREOF Casma Therapeutics, Inc. (US) 2026-04-08 EP disclosed
EP-4712948-A2 GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME Renagade Therapeutics Management Inc. (US) 2026-03-25 EP disclosed
US-20250282795-A1 EGFR Inhibitors in cancer treatment CELYN THERAPEUTICS, INC. 2025-09-11 US disclosed
US-20250170248-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-29 US disclosed
WO-1995022330-A1 ANTIVIRAL AGENTS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1995-08-24 WO disclosed
WO-1995021815-A1 CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE ABBOTT LABORATORIES (US) 1995-08-17 WO disclosed
EP-0420806-B1 Phosphonic acids, process for preparation and use as an active pharmaceutical composition CIBA GEIGY AG (CH) 1995-07-05 EP disclosed
US-5294734-A 1-phosphato-4-amino-pent-2-enoic acids and derivatives CIBA-GEIGY CORP. (US) 1994-03-15 US disclosed
EP-0420806-A1 Phosphonic acids, process for preparation and use as an active pharmaceutical composition CIBA-GEIGY AG (CH) 1991-04-03 EP disclosed
JP-S58152829-A 1,2,3,7,8,8A-HEXAHYDRO-1-HYDROXY-7-METHYL-8-(3'-HYDROXY) PROPYLNAPHTHALENE SUNTORY LTD 1983-09-10 JP disclosed
US-4131623-A FROM DIHYDRO-1,3-OXAZINES, DECYCLIZATION BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL & MECHANICAL COLLEGE (US) 1978-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170248-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 TSHR 4388/4885L3MBTL1 2934/4885TDP1 151/4885
US-20250282795-A1 EGFR Inhibitors in cancer treatment EGFR, ERBB2, ERBB4 TSHR 1283/4885L3MBTL1 4099/4885TDP1 3957/4885
US-20140357872-A1 NEW ORGANOCATALYTIC SYNTHESIS OF CHIRAL PYRAZOLIDINES AND THEIR ANALOGUES PDK2, PDXK, TALDO1 TSHR 2344/4885L3MBTL1 3177/4885TDP1 2876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.